Hepatitis B vaccines/tetanus vaccine/tick-borne encephalitis vaccine
- PDF / 141,768 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 12 Downloads / 193 Views
1
Hepatitis B vaccines/tetanus vaccine/ tick-borne encephalitis vaccine Cutaneous B-cell pseudolymphoma: 4 case reports Four women developed cutaneous B-cell pseudolymphoma at a vaccination site in their upper arms following immunisation with a hepatitis-B vaccine, tick-borne encephalitis vaccine (early summer meningoencephalitis) or a tetanus vaccine [dosage and time to reaction onset not stated; see table for patient characteristics]. Patient 2 developed a pseudolymphoma after receiving tick-borne encephalitis vaccine in her left arm; 4 years later, a second injection of the vaccine was given in her right arm and a pseudolymphoma at the new injection site developed. Pseudolymphoma only developed after the third tetanus vaccine injection in patient 4. On immunohistology. all patients had mixed-cell infiltration with T- and B-cell lymphocytes. The lesion persisted 6 months after presentation in patient 4. Symptom resolution was noted 12 and 72 months after first observation in patients 3 and 2, respectively. Follow-up was not available for patient 4.
Patients characteristics Patient
Age
Vaccine
Clinical features
Treatment
1
60
Subcutaneous nodule
n/a
2
31
Subcutaneous nodule
Radiotherapy*
3
38
Tick-borne encephalitis vaccine Tick-borne encephalitis vaccine Tetanus vaccine
Radiotherapy
4
19
Indurated erythematous plaque Subcutaneous nodule
Hepatitis B vaccine
No treatment
*patient 2 also received radiotherapy to the contralateral arm because lesions from the second pseudolymphoma had not resolved 35 months after onset
Cerroni L, et al. Cutaneous B-cell pseudolymphoma at the site of vaccination. American Journal of Dermatopathology 29: 538-542, No. 6, Dec 2007 801079560 Austria
0114-9954/10/1184-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 12 Jan 2008 No. 1184
Data Loading...
